Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia.
- Author:
Miao-Miao ZHENG
1
;
Li-Jie YUE
;
Xiao-Wen CHEN
;
Fei-Qiu WEN
;
Chang-Gang LI
;
Chun-Lan YANG
;
Cai XIE
;
Hui DING
Author Information
- Publication Type:Journal Article
- MeSH: Antimetabolites, Antineoplastic; adverse effects; Child; Child, Preschool; Female; Genotype; Humans; Male; Methotrexate; adverse effects; Methylenetetrahydrofolate Reductase (NADPH2); genetics; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; drug therapy; genetics; Reverse Transcriptase Polymerase Chain Reaction
- From: Chinese Journal of Contemporary Pediatrics 2013;15(3):201-206
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and toxicities after high-dose methotrexate (HD-MTX) infusion in children with acute lymphocytic leukemia (ALL).
METHODSMTHFR variants in 52 children with ALL were determined by reverse transcriptase-polymerase chain reaction-denaturing gradient gel electrophoresis and sequencing. Toxicities of children who received HD-MTX chemotherapy were evaluated according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC).
RESULTSThe children carrying MTHFR 1298AC had a higher risk of developing thrombocytopenia compared with the carriers of the 1298 AA genotype (OR=13.7, 95%CI=1.18-159.36, P=0.036). There was no significant difference in HD-MTX chemotherapy-related adverse effects between the patients with different MTHFR C677T or G1793A genotypes.
CONCLUSIONSMTHFR A1298C polymorohism may associate with the toxicity of HD-MTX chemotherapy in children with ALL.
